An ASCO Primer: Which Drug Makers are Pursuing Which Kinds of Therapies.
An article by the Wall Street Journal complied with the help of Datamonitor Healthcare
Datamonitor Healthcare was proud to assist the Wall Street Journal in compiling a fascinating article on cancer immunotherapy. You can read a quick extract below, but make sure you click to read the full article – it’s not one you’d want to miss out on.
“Cancer immunotherapy refers to treatments that make the body’s immune system better at fighting tumors. Researchers believe these approaches could dramatically improve prospects for patients, which is why the latest clinical data will be closely scrutinized at the annual meeting of the American Society of Clinical Oncology under way this week end.
But it is a broad church. Researchers are exploring all sorts of strategies to overcome stealth tactics used by tumor cells and to enhance the body’s own immune response. And it remains to be seen which will win out in the end or whether combination therapies could create more powerful effects. Here’s a round-up of approaches taken by numerous drug makers, compiled with the help of Datamonitor Healthcare.”
To read the full article from the Wall Street Journal, compiled with the help of Datamonitor Healthcare, click here >>
[Extract taken from An ASCO Primer: Which Drug Makers are Pursuing Which Kinds of Therapies by Denise Roland, Wall Street Journal]